Marshall Fordyce sold $1.5M of VERA
PRESIDENT AND CEO at Vera Therapeutics, Inc.. 30,625 shares at an average of $49.50, traded Nov 13, 2024, filed Nov 15, 2024.
Score components
- +25RoleCEO
- +25Trade size$1.5M at market
- +10Share of holdings soldSold 31% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.8%, 3m -40.6%, 6m -54.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-026944, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | MOption exercise Class A Common Stock10b5-1 | +12,218 | $2.90 | $35k | 98,160 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -12,218 | $49.54 | $605k | 85,942 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Class A Common Stock10b5-1 | +3,307 | $2.90 | $9,580 | 89,249 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -3,307 | $50.28 | $166k | 85,942 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Class A Common Stock10b5-1 | +100 | $2.90 | $290 | 86,042 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -100 | $51.20 | $5,120 | 85,942 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Class A Common Stock10b5-1 | +1,565 | $2.90 | $4,533 | 87,507 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,565 | $49.59 | $78k | 85,942 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Class A Common Stock10b5-1 | +310 | $2.90 | $898 | 86,252 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -310 | $50.35 | $16k | 85,942 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Class A Common Stock10b5-1 | +1,875 | $2.90 | $5,432 | 87,817 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,875 | $49.57 | $93k | 85,942 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Class A Common Stock10b5-1 | +1,875 | $2.90 | $5,432 | 87,817 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,875 | $49.52 | $93k | 85,942 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Class A Common Stock10b5-1 | +1,875 | $2.90 | $5,432 | 87,817 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -1,875 | $49.50 | $93k | 85,942 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Class A Common Stock10b5-1 | +7,500 | $2.90 | $22k | 93,442 | Nov 15, 2024 |
| Nov 13, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -7,500 | $49.00 | $368k | 85,942 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,625 | $0.00 | $0 | 753,587 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,875 | $0.00 | $0 | 751,712 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,875 | $0.00 | $0 | 749,837 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,875 | $0.00 | $0 | 747,962 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,875 | $0.00 | $0 | 746,087 | Nov 15, 2024 |
| Nov 13, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 738,587 | Nov 15, 2024 |
Related signals
Other insiders at Vera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $685k 18,500 shares | -7% | |
| 10Weak | Vera Therapeutics, Inc. | Marshall Fordyce PRESIDENT AND CEO | $650k 18,500 shares | -7% | |
| 24Weak | VERAsell Vera Therapeutics, Inc. | Robert Brenner Chief Medical Officer | $90k 2,151 shares | -4% | |
| 8Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $501k 10,000 shares | -31% | |
| 36Weak | VERAbuy Vera Therapeutics, Inc. | Patrick G Enright director | $250k 5,882 shares | - | |
| 7Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $453k 10,000 shares | -31% | |
| 14Weak | Vera Therapeutics, Inc. | William D. Turner Chief Regulatory Officer | $400k 10,000 shares | -31% | |
| 40Moderate | Vera Therapeutics, Inc. | Jason S Carter Chief Legal Officer | $107k 3,864 shares | -7% | |
| 30Weak | Vera Therapeutics, Inc. | Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR | $436k 15,000 shares | -24% | |
| 51Moderate | VERAbuy Vera Therapeutics, Inc. | Patrick G Enright director | $5.3M 250,000 shares | +15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.